An observational study in Hypertension, sponsored by Bayer. Completed at 4 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-01-20.
Sponsored by Bayer · Observational
The main purpose of this study is to asses the efficacy and safety of telmisartan, with the special attention on the influence of telmisartan on selected metabolic parameters of patients.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 5,448 is above the median of 210 across 1,359 observational studies indexed under Hypertension.
Browse Hypertension studies →Bayer is the lead sponsor of 1,643 studies on the registry; 57 are open to participants now.
Of its 209 completed or terminated interventional studies of FDA-regulated products, 129 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Primary care clinic
Exclusion Criteria:
Drug: Pritor (Telmisartan , BAY68-9291)
Primary care hypertensive patients starting the therapy with Telmisartan
Efficacy and safety of the treatment with telmisartan reported by the physician
Time frame: At the both of planned control visits. (Approx. interval between visits 3 months)
Changes in metabolic parameters in telmisartan treated patients
Time frame: At the both of planned control visits. (Approx. interval between visits 3 months)
This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bayer